Concepedia

Å. Bratland

ÅB

Statistics

Publications

4

Citations

3.6K

H-Index

4

Active since

2018

Affiliations

Royal Brisbane and Women's Hospital(Current)

The University of Queensland

Merck & Co., Inc., Rahway, NJ, USA (United States)

University Hospital of Zurich

Instituto do Câncer do Estado de São Paulo

Å. Bratland is an author at Royal Brisbane and Women's Hospital specializing in squamous cell carcinoma, oncology, and pembrolizumab therapy.

Publications per year

2018–2021

4

Publications

4

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

, , +11

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial

Brett Hughes, Laurent Mortier, Å. Bratland et al. · Annals of Oncology · 2021 · 200 citations

, , +17

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · Annals of Oncology · 2018 · 138 citations

, , +15

915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

Richard Greil, Danny Rischin, Kevin J. Harrington et al. · Annals of Oncology · 2020 · 11 citations

, , +16

1–4 of 4